Quick Takeaways
- Akero Therapeutics, Inc. has 17 insiders with reported activity on this page.
- Net insider value flow over the last year: -$20,333,700.
- Recent transaction rows are available for direct filing-level review.
Insider Transactions Reported by 17 Insiders of Akero Therapeutics, Inc.
- Location
- South San Francisco, CA
What Changed
- Buy value: ; sell value: $20,333,699.
- Net share flow: -414,409.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Source Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsNet insider flow leans to selling over the last 12 months. Net value: -$20,333,700.
Buys
$0
Shares: 0
Insiders: 0
Sells
$20,333,700
Shares: 414,409
Insiders: 8
Net
-$20,333,700
Shares: -414,409
Insiders: -8
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 172,253 | $0 | $8,214,449 | -$8,214,449 |
| 9-12 | 0 | 242,156 | $0 | $12,119,251 | -$12,119,251 |
Akero Therapeutics, Inc. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Skorpios Trust | Former 10% owner | $2,012,175 | Mixed | 01 Dec 2022 | ||
| Andrew Cheng | President and CEO, Director | $0 | -$9,638,932 | -100% | Mixed | 09 Dec 2025 |
| G. Walmsley Graham | Director | $0 | Mixed | 09 Dec 2025 | ||
| Jonathan Young | Chief Operating Officer | $0 | -$2,009,836 | -100% | Mixed | 09 Dec 2025 |
| Patrick Lamy | Senior VP, Commercial Strategy | $0 | -$1,052,630 | -100% | Mixed | 09 Dec 2025 |
| Catriona Yale | Chief Development Officer | $0 | -$1,734,006 | -100% | Mixed | 09 Dec 2025 |
| Chou Judy | Director | $0 | Mixed | 09 Dec 2025 | ||
| Scott A. Gangloff | Chief Technology Officer | $0 | -$46,504 | -100% | Mixed | 09 Dec 2025 |
| Iwicki Mark T. | Director | $0 | Mixed | 09 Dec 2025 | ||
| Yuan Xu | Director | $0 | Mixed | 09 Dec 2025 | ||
| Tomas J. Heyman | Director | $0 | Mixed | 09 Dec 2025 | ||
| William Richard White | Chief Financial Officer | $0 | -$269,361 | -100% | Mixed | 09 Dec 2025 |
| Seth Loring Harrison | Director | $0 | Mixed | 09 Dec 2025 | ||
| Timothy Rolph | Chief Scientific Officer | $0 | -$5,440,060 | -100% | Mixed | 09 Dec 2025 |
| Jane Pritchett Henderson | Director | $0 | -$142,371 | -100% | Mixed | 09 Dec 2025 |
| Kevin Bitterman | Director | Mixed | 01 Jun 2021 | |||
| ATP Life Science Ventures, L.P. | 10%+ Owner | Mixed | 28 Jun 2021 |
Top shareholders of Akero Therapeutics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| GENERAL ATLANTIC, L.P. |
13D/G
|
— |
8.4%
|
6,796,489
|
$278,656,049 | $0 | 31 Mar 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13D/G
|
T. Rowe Price Associates, Inc. |
4.8%
|
3,810,076
|
$180,902,408 | $0 | 30 Sep 2025 | |
| JANUS HENDERSON GROUP PLC |
13D/G
|
— |
4.1%
|
3,397,779
|
$138,062,973 | -$117,126,544 | 31 Dec 2025 | |
| Skorpios Trust |
3/4/5
|
Former 10% owner |
—
class O/S missing
|
3,271,829
|
$2,012,175 | — | 01 Dec 2022 | |
| Deutsche Girozentrale DekaBank |
13F
|
Individual |
0.02%
|
20,000
|
$532,000 | — | 31 Dec 2025 | |
| IFP Advisors, Inc |
13F
|
Company |
0%
|
18
|
$984 | — | 31 Dec 2025 | |
| Kevin Bitterman |
3/4/5
|
Director |
—
class O/S missing
|
13,000
|
— | — | 01 Jun 2021 |
Recent Insider Transactions by Companies or Individuals for Akero Therapeutics, Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Tomas J. Heyman | AKRO | Common Stock | Disposed to Issuer | -100% | -9,398 | 0 | 09 Dec 2025 | Direct | ||
| Tomas J. Heyman | AKRO | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -69,000 | 0 | 09 Dec 2025 | Direct | ||
| Yuan Xu | AKRO | Common Stock | Disposed to Issuer | -100% | -9,398 | 0 | 09 Dec 2025 | Direct | ||
| Yuan Xu | AKRO | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -95,000 | 0 | 09 Dec 2025 | Direct | ||
| Andrew Cheng | AKRO | Common Stock | Disposed to Issuer | -100% | -436,837 | 0 | 09 Dec 2025 | Direct | ||
| Andrew Cheng | AKRO | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -1,678,754 | 0 | 09 Dec 2025 | Direct | ||
| Seth Loring Harrison | AKRO | Common Stock | Disposed to Issuer | -100% | -148,063 | 0 | 09 Dec 2025 | See Footnote | ||
| Seth Loring Harrison | AKRO | Common Stock | Disposed to Issuer | -100% | -145,699 | 0 | 09 Dec 2025 | Direct | ||
| Seth Loring Harrison | AKRO | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -108,000 | 0 | 09 Dec 2025 | Direct | ||
| G. Walmsley Graham | AKRO | Common Stock | Disposed to Issuer | -100% | -1,200,000 | 0 | 09 Dec 2025 | See Footnote | ||
| G. Walmsley Graham | AKRO | Common Stock | Disposed to Issuer | -100% | -102,398 | 0 | 09 Dec 2025 | Direct | ||
| G. Walmsley Graham | AKRO | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -15,000 | 0 | 09 Dec 2025 | Direct | ||
| Chou Judy | AKRO | Common Stock | Disposed to Issuer | -100% | -9,398 | 0 | 09 Dec 2025 | Direct | ||
| Chou Judy | AKRO | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -82,000 | 0 | 09 Dec 2025 | Direct | ||
| Timothy Rolph | AKRO | Common Stock | Disposed to Issuer | -100% | -282,149 | 0 | 09 Dec 2025 | Direct | ||
| Timothy Rolph | AKRO | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -406,014 | 0 | 09 Dec 2025 | Direct | ||
| Iwicki Mark T. | AKRO | Common Stock | Disposed to Issuer | -100% | -9,398 | 0 | 09 Dec 2025 | Direct | ||
| Iwicki Mark T. | AKRO | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -240,307 | 0 | 09 Dec 2025 | Direct | ||
| Scott A. Gangloff | AKRO | Common Stock | Disposed to Issuer | -100% | -26,351 | 0 | 09 Dec 2025 | Direct | ||
| Scott A. Gangloff | AKRO | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -296,100 | 0 | 09 Dec 2025 | Direct | ||
| William Richard White | AKRO | Common Stock | Disposed to Issuer | -100% | -57,752 | 0 | 09 Dec 2025 | Direct | ||
| William Richard White | AKRO | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -661,075 | 0 | 09 Dec 2025 | Direct | ||
| Catriona Yale | AKRO | Common Stock | Disposed to Issuer | -100% | -74,800 | 0 | 09 Dec 2025 | Direct | ||
| Catriona Yale | AKRO | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -456,575 | 0 | 09 Dec 2025 | Direct | ||
| Patrick Lamy | AKRO | Common Stock | Disposed to Issuer | -100% | -29,891 | 0 | 09 Dec 2025 | Direct | ||
| Patrick Lamy | AKRO | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -212,664 | 0 | 09 Dec 2025 | Direct | ||
| Jane Henderson | AKRO | Common Stock | Disposed to Issuer | -100% | -9,398 | 0 | 09 Dec 2025 | Direct | ||
| Jane Henderson | AKRO | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -93,797 | 0 | 09 Dec 2025 | Direct | ||
| Jonathan Young | AKRO | Common Stock | Disposed to Issuer | -100% | -20,000 | 0 | 09 Dec 2025 | By JL Irrevocable Trust | ||
| Jonathan Young | AKRO | Common Stock | Disposed to Issuer | -100% | -20,000 | 0 | 09 Dec 2025 | By CM Irrevocable Trust | ||
| Jonathan Young | AKRO | Common Stock | Disposed to Issuer | -100% | -20,000 | 0 | 09 Dec 2025 | By EA Irrevocable Trust | ||
| Jonathan Young | AKRO | Common Stock | Disposed to Issuer | -100% | -200,189 | 0 | 09 Dec 2025 | Direct | ||
| Jonathan Young | AKRO | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -512,082 | 0 | 09 Dec 2025 | Direct | ||
| Jonathan Young | AKRO | Common Stock | Gift | -4.42% | -9,259 | 200,189 | 26 Nov 2025 | Direct | ||
| Timothy Rolph | AKRO | Common Stock | Options Exercise | 117.9% | 152,678 | 282,149 | 25 Nov 2025 | Direct | ||
| Timothy Rolph | AKRO | Stock Option (Right to Buy) | Options Exercise | -100% | -152,678 | 0 | 25 Nov 2025 | Direct | ||
| Jonathan Young | AKRO | Common Stock | Options Exercise | 6.37% | 12,550 | 209,448 | 24 Nov 2025 | Direct | ||
| Jonathan Young | AKRO | Stock Option (Right to Buy) | Options Exercise | -100% | -12,550 | 0 | 24 Nov 2025 | Direct | ||
| Andrew Cheng | AKRO | Common Stock | Gift | -14.6% | -74,538 | 436,837 | 20 Nov 2025 | Direct | ||
| Timothy Rolph | AKRO | Common Stock | Gift | -22.3% | -37,100 | 129,471 | 17 Nov 2025 | Direct | ||
| Andrew Cheng | AKRO | Common Stock | Gift | -2.8% | -14,739 | 511,375 | 12 Nov 2025 | Direct | ||
| Catriona Yale | AKRO | Common Stock | Options Exercise | 12.4% | 8,266 | 74,800 | 04 Nov 2025 | Direct | ||
| Catriona Yale | AKRO | Stock Option (Right to Buy) | Options Exercise | -100% | -8,266 | 0 | 04 Nov 2025 | Direct | ||
| Andrew Cheng | AKRO | Common Stock | Sale | -5.39% | $1,619,340 | $53.98 | -30,000 | 526,114 | 10 Oct 2025 | Direct |
| Andrew Cheng | AKRO | Common Stock | Options Exercise | 5.7% | 30,000 | 556,114 | 10 Oct 2025 | Direct | ||
| Andrew Cheng | AKRO | Stock Option (Right to Buy) | Options Exercise | -7.32% | -30,000 | 380,017 | 10 Oct 2025 | Direct | ||
| G. Walmsley Graham | AKRO | Common Stock | Options Exercise | 4189.7% | 90,832 | 93,000 | 08 Oct 2025 | Direct | ||
| G. Walmsley Graham | AKRO | Stock Option (Right to Buy) | Options Exercise | -100% | -90,832 | 0 | 08 Oct 2025 | Direct | ||
| Andrew Cheng | AKRO | Common Stock | Options Exercise | 11% | 52,212 | 526,114 | 08 Oct 2025 | Direct | ||
| Andrew Cheng | AKRO | Stock Option (Right to Buy) | Options Exercise | -100% | -52,212 | 0 | 08 Oct 2025 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.